Omega-3 Fatty Acids (EPA/DHA) ： Crohn's Disease
C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
結論
EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
Key Study Findings
Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral
vs: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy
Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH)
効果: None
None
対象集団: DNBS-induced Crohn's disease BALB/c mouse model
Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None
vs: None
Outcome: IBD microbiota modulation and immune regulation
効果: None
None
対象集団: IBD patients (review of nutritional interventions)
Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None
vs: None
Outcome: Athletic performance and nutritional optimization
効果: None
None
対象集団: Vegan athletes (narrative review)
Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None
vs: None
Outcome: Diet-genetics interaction in IBD
効果: None
None
対象集団: IBD patients (editorial commentary)
Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None
vs: None
Outcome: Colitis severity
効果: None
None
対象集団: Crohn's disease patients
Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95%
vs: None
Outcome: inflammation markers
効果: None
None
対象集団: None
Key Statistics
6
研究数
800
参加者数
↔
Mixed
C
グレード
Referenced Papers
Semergen
2025
4 件の引用
Current nutrition reports
2025
3 件の引用
Journal of ethnopharmacology
2025
1 件の引用
Autoimmunity reviews
2024
12 件の引用
World journal of …
2024
Metabolites
2023
13 件の引用
Scientific reports
2020
56 件の引用
Gastroenterology clinics of …
2018
67 件の引用
International journal of …
2017
143 件の引用
Medical principles and …
2017
45 件の引用
Ugeskrift for laeger
2017
European journal of …
2016
79 件の引用
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 件の引用
Clinics in dermatology
2016
19 件の引用
The Cochrane database …
2014
88 件の引用
Alimentary pharmacology & …
2013
128 件の引用
The British journal …
2012
145 件の引用
Dietary supplements for established atopic eczema.
Meta-Analysis
The Cochrane database …
2012
130 件の引用
World journal of …
2012
113 件の引用
Frontline gastroenterology
2012
20 件の引用
Pediatrics in review
2012
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.
Systematic Review
The American journal …
2011
946 件の引用
Inflammatory bowel diseases
2011
195 件の引用
Nutrition in clinical …
2011
1 件の引用
The Cochrane database …
2009
198 件の引用
Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Review
Alimentary pharmacology & …
2008
50 件の引用
The American journal …
2007
310 件の引用
Digestion
2007
15 件の引用
The Cochrane database …
2007
2 件の引用
Gastroenterology nursing : …
2006
24 件の引用
World journal of …
2005
80 件の引用
Alimentary pharmacology & …
2005
50 件の引用
Immunonutrition.
Review
Current opinion in …
2005
22 件の引用
Nutricion hospitalaria
2003
Journal of the …
2002
2016 件の引用
Enteral feeding.
Other
Current opinion in …
2002
1 件の引用
Enteral feeding.
Review
Current opinion in …
2002
Zeitschrift fur Gastroenterologie
1998
18 件の引用
Scandinavian journal of …
1996
195 件の引用
Arquivos de gastroenterologia
1996
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
上限量： 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| 50, 100, and 200 mg/kg oral | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | -- |
| None | -- | Mixed | 12194 |
| None | -- | Mixed | -- |
推奨摂取タイミング： With meals containing fat for better absorption
Safety & Side Effects
報告されている副作用
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
既知の相互作用
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
耐容上限摂取量： 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
Based on 6 studies with 800 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.
Related Evidence
に関する他の成分： Crohn's Disease
Omega-3 Fatty Acids (EPA/DHA) 他の症状・状態について
References
- [1] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
- [2] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
- [3] Mohamed Sofiane Merakeb et al.. J Ethnopharmacol. 2025. Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. (flaxseed) in vivo. doi:10.1016/j.jep.2025.120001 PubMed
- [4] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
- [5] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
- [6] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
- [7] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
- [8] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [9] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
- [10] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
- [11] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
- [12] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
- [13] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
- [14] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
- [15] Raffi Lev-Tzion et al.. Cochrane Database Syst Rev. 2014. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub4 PubMed
- [16] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
- [17] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [18] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
- [19] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [20] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [21] Alycia Leiby et al.. Pediatr Rev. 2012. Complementary, holistic, and integrative medicine: Crohn disease. doi:10.1542/pir.33-2-83 PubMed
- [22] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
- [23] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
- [24] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
- [25] Dan Turner et al.. Cochrane Database Syst Rev. 2009. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub3 PubMed
- [26] A K Akobeng. Aliment Pharmacol Ther. 2008. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. doi:10.1111/j.1365-2036.2007.03536.x PubMed
- [27] Devendra K Amre et al.. Am J Gastroenterol. 2007. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. doi:10.1111/j.1572-0241.2007.01411.x PubMed
- [28] Aneta Aleksandra Nielsen et al.. Digestion. 2007. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin … doi:10.1159/000101560 PubMed
- [29] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub2 PubMed
- [30] Angie Macdonald. Gastroenterol Nurs. 2006. Omega-3 fatty acids as adjunctive therapy in Crohns disease. doi:10.1097/00001610-200607000-00005 PubMed
- [31] C Romano et al.. World J Gastroenterol. 2005. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, … doi:10.3748/wjg.v11.i45.7118 PubMed
- [32] A A Nielsen et al.. Aliment Pharmacol Ther. 2005. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. doi:10.1111/j.1365-2036.2005.02698.x PubMed
- [33] Robert F Grimble. Curr Opin Gastroenterol. 2005. Immunonutrition. doi:10.1097/01.mog.0000153360.90653.82 PubMed
- [34] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
- [35] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
- [36] Khursheed N Jeejeebhoy. Curr Opin Gastroenterol. 2002. Enteral feeding. doi:10.1097/00001574-200203000-00010 PubMed
- [37] Khursheed N Jeejeebhoy. Curr Opin Clin Nutr Metab Care. 2002. Enteral feeding. doi:10.1097/00075197-200211000-00013 PubMed
- [38] D Schwab et al.. Z Gastroenterol. 1998. [Enteral nutrition in acute Crohn disease]. PubMed
- [39] H Lorenz-Meyer et al.. Scand J Gastroenterol. 1996. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study … doi:10.3109/00365529609010352 PubMed
- [40] C Cukier et al.. Arq Gastroenterol. 1996. [Biological activity of fish oil]. PubMed
- [41] J Vilaseca et al.. Gut. 1990. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. doi:10.1136/gut.31.5.539 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。